Medical devices, healthcare technology and the business of care
PMA approval · P150012

IMAGEREADY MR CONDITIONAL PACING SYSTEM AND INGEVITY PACE/SENSE LEAD

Boston Scientific · Decision date Apr 25, 2016

MEDTECHLEDGER EXPLANATIONP150012

What did the FDA approve?

FDA approved Boston Scientific's ImageReady MR Conditional Pacing System under P150012 on April 25, 2016. The approval covers pacing indications for symptomatic AV block, bundle branch block, sinus node dysfunction, bradycardia-tachycardia syndrome, and neurovascular or carotid sinus syndromes, plus adaptive-rate pacing for chronotropic incompetence. Dual-chamber and atrial tracking modes are indicated for maintaining AV synchrony, VVI intolerance, and low cardiac output or congestive heart failure secondary to bradycardia.

The approval also covers Ingevity pace/sense leads. Passive-fixation non-MRI models 7631, 7632, 7635, 7636 and MRI models 7731, 7732, 7735, 7736 are indicated for chronic pacing and sensing in the right atrium (Preformed Atrial J) or right ventricle (Straight). Active-fixation non-MRI models 7640, 7641, 7642 and MRI models 7740, 7741, 7742 are indicated for chronic pacing and sensing in the right atrium and/or right ventricle. Accessories include a slit suture sleeve and delivery stylet.

FDA approval order statement

Approval for The ImageReady MR Conditional Pacing System. The device is indicated for the treatment of the following conditions:1) Symptomatic paroxysmal or permanent second- or third-degree AV block;2) Symptomatic bilateral bundle branch block;3) Symptomatic paroxysmal or transient sinus node dysfunction with or without associated AV conduction disorders (i.e., sinus bradycardia, sinus arrest, sinoatrial [SA] block);4) Bradycardia-tachycardia syndrome, to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias; and5) Neurovascular (vaso-vagal) syndromes or hypersensitive carotid sinus syndromes.Adaptive-rate pacing is indicated for patients exhibiting chronotropic incompetence and who may benefit from increased pacing rates concurrent with increases in minute ventilation and/or level of physical activity.Dual-chamber and atrial tracking modes are also indicated for patients who may benefit from maintenance of AV synchrony.Dual chamber modes are specifically indicated for treatment of the following:1) Conduction disorders that require restoration of AV synchrony, including varying degrees of AV block;2) VVI intolerance (i.e., pacemaker syndrome) in the presence of persistent sinus rhythm; and3) Low cardiac output or congestive heart failure secondary to bradycardia. Passive-fixation Non-MRI Models 7631, 7632, 7635 and 7636 and MRI Models 7731, 7732, 7735 and 7736 are indicated for chronic pacing and sensing in the right atrium (Preformed Atrial J) or right ventricle (Straight) when used with a compatible pulse generator.Active-fixation Non-MRI Models 7640, 7641, and 7642 and MRI Models 7740, 7741, and 7742 are indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.The intended use of the slit suture sleeve accessory is to secure and immobilize Boston Scientific Ingevity leads at the venous entry site.The delivery stylet accessory is indicated for use with Boston Scientific implantable transvenous leads.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Apr 25, 2016

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150012
Regulatory pathway
Premarket approval application
Product code
LWP
Decision code
APPR
Decision date
Apr 25, 2016
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable pulse generator, pacemaker (non-CRT).

Product code
LWP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P150012 received

    Application receipt date recorded by FDA.

  2. P150012 · FDA decision

    APPR

  3. P150012/S191 · Related supplement

    ESSENTIO MRI (Model L131); PROPONENT MRI (Model L231); ACCOLADE MRI (Model L331); ESSENTIO MRI (Models L110, L111); PRO

Timeline entries are records held by MedtechLedger for P150012. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150012

Product / regulatory recordCompanyPathwayDecision dateSource
Boston ScientificPMA supplementOct 3, 2026FDA

Explore the linked device profile

Other records with product code LWP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records